Literature DB >> 21954429

The natural history of infant spinal muscular atrophy in China: a study of 237 patients.

Xiushan Ge1, Jinli Bai, Yanyu Lu, Yujin Qu, Fang Song.   

Abstract

The authors retrospectively studied the natural history of 237 patients with infantile spinal muscular atrophy in China. The onset ages (mean ± SD) for types I to III were 3.1 ± 2.7, 8.7 ± 3.8, and 21.1 ± 11.7 months, respectively. The survival probabilities for type I patients at 1, 2, and 5 years were 44.9%, 38.1%, and 29.3%, respectively, and for type II patients, the probabilities were 100%, 100%, and 97%, respectively. All type III patients were alive. Type I patients with onset age after 2 months had significantly increased survival than those with onset before 2 months (P < .05). It should be noticed that survival probability at 2 years in type I patients in our study was close to that in other Asian samples of spinal muscular atrophy, but slightly better than that among whites. Patients accepted minimal proactive interventions other than antibiotics for pulmonary infection, so our study provides reliable baseline data of natural history of spinal muscular atrophy in China.

Entities:  

Mesh:

Year:  2011        PMID: 21954429     DOI: 10.1177/0883073811420152

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  7 in total

1.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

Review 2.  New therapeutic approaches to spinal muscular atrophy.

Authors:  Aga Lewelt; Tara M Newcomb; Kathryn J Swoboda
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

3.  Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States.

Authors:  Cathy Lally; Cynthia Jones; Wildon Farwell; Sandra P Reyna; Suzanne F Cook; W Dana Flanders
Journal:  Orphanet J Rare Dis       Date:  2017-11-28       Impact factor: 4.123

4.  New insights into SMA pathogenesis: immune dysfunction and neuroinflammation.

Authors:  Marc-Olivier Deguise; Rashmi Kothary
Journal:  Ann Clin Transl Neurol       Date:  2017-05-18       Impact factor: 4.511

5.  Natural history of lung function in spinal muscular atrophy.

Authors:  Camiel A Wijngaarde; Esther S Veldhoen; Ruben P A van Eijk; Marloes Stam; Louise A M Otto; Fay-Lynn Asselman; Roelie M Wösten-van Asperen; Erik H J Hulzebos; Laura P Verweij-van den Oudenrijn; Bart Bartels; Inge Cuppen; Renske I Wadman; Leonard H van den Berg; Cornelis K van der Ent; W Ludo van der Pol
Journal:  Orphanet J Rare Dis       Date:  2020-04-10       Impact factor: 4.123

6.  Eighteen Years with Spinal Muscular Atrophy (SMA) Type 1.

Authors:  Borja Valencia; John Robert Bach
Journal:  Tanaffos       Date:  2013

7.  Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy.

Authors:  Giovanni Baranello; Ksenija Gorni; Monica Daigl; Anna Kotzeva; Rachel Evans; Neil Hawkins; David A Scott; Anadi Mahajan; Francesco Muntoni; Laurent Servais
Journal:  Clin Pharmacol Ther       Date:  2021-06-05       Impact factor: 6.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.